DDInter122 DDInter1281
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.
Neratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Neratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Neratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Neratinib {u} may lead to a major life threatening interaction when taken with {v} Colchicine
Neratinib {u} may lead to a major life threatening interaction when taken with {v} Fedratinib
Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Neratinib may lead to a major life threatening interaction when taken with Colchicine
Neratinib may lead to a major life threatening interaction when taken with Fedratinib